#4 Digital Health Inside Out Interviews: Is the Symptom Checker Dead? Infermedica CEO Piotr Orzechowski on AI Triage & Medical AI

#4 Digital Health Inside Out Interviews: Is the Symptom Checker Dead? Infermedica CEO Piotr Orzechowski on AI Triage & Medical AI

In this episode of Digital Health Inside Out, Alex Koshykov and Sergei Polevikov sit down with Piotr Orzechowski, founder and CEO of Infermedica, one of the most established companies in AI-powered symptom assessment and clinical triage.We discuss how the symptom-checker category has changed, why standalone consumer symptom checkers may be “dead,” and why clinical-grade AI triage is still becoming more important within real healthcare workflows.Piotr shares the story of building Infermedica from Poland into a global healthtech company, the challenges of selling medical AI internationally, how Infermedica competes in the age of ChatGPT and LLMs, and why medical device certification, physician validation, liability, and evidence still matter.We also cover AI accuracy claims, peer-reviewed validation, neurosymbolic AI, voice-based triage, fundraising for founders from Eastern Europe, the future of AI diagnosis, and what kind of companies might eventually acquire Infermedica.If you care about healthcare AI, digital health, symptom checkers, clinical triage, LLMs in medicine, or the future of regulated medical AI, this conversation is for you.

GLP-1s: Are We Outsourcing Willpower to Pharma?

GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound have become one of the biggest stories in healthcare, obesity medicine, pharma, telehealth, and even culture.But are GLP-1s truly transforming obesity care — or are we outsourcing willpower to pharma?In this episode of Digital Health Inside Out, Alex Koshykov and Sergey Polevikov sit down with Dr. Beverly Chang, Dave Knapp, and Sean Sullivan to unpack the science, business, safety concerns, access issues, and social debate around GLP-1 medications.

#6 Digital Health Vitals: Payer Earnings, Funding Rounds, AI Upcoding, CMS ACCESS & Hippocratic AI

In this episode of Digital Health Vitals, we break down the biggest stories shaping digital health, healthcare AI, health tech investing, payer strategy, value-based care, and digital health startup funding in 2026. If you’re interested in AI in healthcare, digital health funding, healthcare startups, value-based care, payer-provider dynamics, clinical AI, healthcare public markets, or health tech business models, this episode is for you.

#3 Digital Health Inside Out Interviews: Christina Farr on AI Scribes, IPO Windows, Big Tech Failures, and Health Tech Media

What happens when one of digital health’s sharpest observers sits down to talk about AI hype, health tech media, IPOs, storytelling, and the future of the industry?In this episode of Digital Health Inside Out, we speak with Christina Farr, a former CNBC reporter, CEO of Second Opinion, and GP at Scrub Capital, advisor, podcaster, and one of the most thoughtful voices in healthcare innovation.We talked about Christina’s transition from journalism into venture and media, whether she could have had a bigger impact by staying in reporting, the problem with how healthcare AI talks about job loss, why most companies still tell bad stories, what founders should share more openly, whether the digital health IPO window is really reopening, why Big Tech keeps struggling in healthcare, and whether AI scribes are a real breakthrough or just the latest wave of hype.This was an honest, nuanced, and at times uncomfortable conversation — exactly the kind we like to have on this channel.If you enjoy candid conversations about digital health, healthcare AI, startups, venture capital, and the realities behind the headlines, subscribe to the channel.

#2 Digital Health Inside Out Interviews: Shiv Rao on Building Abridge and Scaling AI Across 250+ Health Systems

In this episode of Digital Health Interviews, we sit down with Shiv Rao, CEO and co-founder of Abridge, to talk about the real future of ambient AI in healthcare. We also get into some of the harder questions: valuation hype, investor influence, FDA regulation, liability, Epic’s role in the market, and what healthcare may look like as AI becomes more deeply embedded into clinical workflows.